The Chemours Company

Quarterly Financial Information

May 4, 2018

Safe Harbor Statement

This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," “will,” "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans and prospects, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, and our outlook for net sales, Adjusted EBITDA, Adjusted EPS, Free Cash Flow, and Return on Invested Capital, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2017. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

Non-GAAP Financial Measures

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”). Within this presentation, we may make reference to Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, ROIC and Net Leverage Ratio to evaluate the company’s performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Accordingly, the company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the company’s operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the company’s financial statements and footnotes contained in the documents that the company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the company in this press release may be different from the methods used by other companies. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, “Reconciliation of Non-GAAP Financial Measures to GAAP Financial Measures” and materials posted to the company’s website at investors.chemours.com.

Chemours™

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Dollars in millions, except per share amounts)

	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Net sales	$ 1,730	**$ 6,183**	$ 1,575	$ 1,584	$ 1,588	$ 1,437	**$ 5,400**	$ 1,322	$ 1,398	$ 1,383	$ 1,297
Cost of goods sold	1,193	**4,438**	1,090	1,119	1,150	1,081	**4,297**	1,023	1,058	1,118	1,100
Gross profit	537	**1,745**	485	465	438	356	**1,103**	299	340	265	197
Selling, general, and administrative expense	143	**626**	165	153	159	150	**946**	480	151	178	135
Research and development expense	20	**81**	20	20	21	19	**81**	20	19	17	23
Restructuring, asset-related, and other charges, net	10	**57**	26	8	11	12	**170**	25	60	67	17
Total expenses	173	**764**	211	181	191	181	**1,197**	525	230	262	175
Equity in earnings of affiliates	12	**33**	7	9	10	7	**29**	12	9	4	5
Interest expense, net	(52)	**(215)**	(54)	(55)	(55)	(51)	**(213)**	(56)	(51)	(50)	(57)
Other income (expense), net	57	**113**	37	12	23	42	**267**	(3)	166	2	100
Income (loss) before income taxes	381	**912**	264	250	225	173	**(11)**	(273)	234	(41)	70
Provision for (benefit from) income taxes	84	**165**	36	43	64	22	**(18)**	(43)	30	(23)	19
Net income (loss)	297	**747**	228	207	161	151	**7**	(230)	204	(18)	51
Less: Net income attributable to non-controlling interests	-	**1**	-	-	-	1	**-**	-	-	-	-
Net income (loss) attributable to Chemours	$ 297	**$ 746**	$ 228	$ 207	$ 161	$ 150	**$ 7**	$ (230)	$ 204	$ (18)	$ 51
Per share data											
Basic earnings (loss) per share of common stock	$ 1.63	**$ 4.04**	$ 1.23	$ 1.12	$ 0.87	$ 0.82	**$ 0.04**	$ (1.26)	$ 1.12	$ (0.10)	$ 0.28
Diluted earnings (loss) per share of common stock	1.58	**3.91**	1.19	1.08	0.84	0.79	**0.04**	(1.26)	1.11	(0.10)	0.28
Dividends per share of common stock	-	**0.29**	0.20	0.03	0.03	0.03	**0.12**	0.03	0.03	0.03	0.03

***** Note: Individual quarters may not sum to the full year amounts due to rounding.

CONSOLIDATED BALANCE SHEETS
(Dollars in millions, except per share amounts)

	(Unaudited) March 31, 2018	December 31, 2017	December 31, 2016
Assets			
Current assets:			
Cash and cash equivalents	$ 1,434	$ 1,556	$ 902
Accounts and notes receivable, net	1,083	919	807
Inventories	992	935	767
Prepaid expenses and other	75	83	77
Total current assets	3,584	3,493	2,553
Property, plant, and equipment	8,719	8,511	7,997
Less: Accumulated depreciation	(5,614)	(5,503)	(5,213)
Property, plant, and equipment, net	3,105	3,008	2,784
Goodwill and other intangible assets, net	165	166	170
Investments in affiliates	166	173	136
Other assets	464	453	417
Total assets	$ 7,484	$ 7,293	$ 6,060
Liabilities			
Current liabilities:			
Accounts payable	$ 1,121	$ 1,075	$ 884
Current maturities of long-term debt	14	15	15
Other accrued liabilities	487	558	872
Total current liabilities	1,622	1,648	1,771
Long-term debt, net	4,141	4,097	3,529
Deferred income taxes	244	208	132
Other liabilities	475	475	524
Total liabilities	6,482	6,428	5,956
Commitments and contingent liabilities			
Equity			
Common stock (par value $0.01 per share; 810,000,000 shares authorized)	2	2	2
Treasury stock at cost	(361)	(116)	-
Additional paid-in capital	846	837	789
Retained earnings (accumulated deficit)	876	579	(114)
Accumulated other comprehensive loss	(366)	(442)	(577)
Total Chemours stockholders' equity	997	860	100
Non-controlling interests	5	5	4
Total equity	1,002	865	104
Total liabilities and equity	$ 7,484	$ 7,293	$ 6,060

Chemours

SEGMENT NET SALES (UNAUDITED)
(Dollars in millions)

	LTM* 1Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Fluoroproducts	$ 2,735	$ 732	$ 2,654	$ 656	$ 637	$ 710	$ 652	$ 2,264	$ 569	$ 591	$ 573	$ 531
Chemical Solutions	575	144	571	134	148	149	139	772	130	182	214	245
Titanium Technologies	3,167	854	2,958	785	799	729	646	2,364	623	625	596	521
TOTAL CHEMOURS	$ 6,477	$ 1,730	$ 6,183	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 5,400	$ 1,322	$ 1,398	$ 1,383	$ 1,297

SEGMENT ADJUSTED EBITDA (UNAUDITED)
(Dollars in millions)

	LTM* 1Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Fluoroproducts	$ 720	$ 206	$ 669	$ 159	$ 158	$ 197	$ 155	$ 445	$ 111	$ 143	$ 105	$ 85
Chemical Solutions	56	11	57	20	18	7	12	39	9	9	11	10
Titanium Technologies	997	294	862	261	249	193	159	466	157	144	111	54
Corporate and Other	(169)	(43)	(166)	(46)	(44)	(36)	(41)	(128)	(38)	(28)	(40)	(21)
TOTAL CHEMOURS	$ 1,604	$ 468	$ 1,422	$ 394	$ 381	$ 361	$ 285	$ 822	$ 239	$ 268	$ 187	$ 128

SEGMENT ADJUSTED EBITDA MARGIN (UNAUDITED)

	LTM* 1Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Fluoroproducts	26.3%	28.1%	25.2%	24.2%	24.8%	27.7%	23.8%	19.7%	19.5%	24.2%	18.3%	16.0%
Chemical Solutions	9.7%	7.6%	10.0%	14.9%	12.2%	4.7%	8.6%	5.1%	6.9%	4.9%	5.1%	4.1%
Titanium Technologies	31.5%	34.4%	29.1%	33.2%	31.2%	26.5%	24.6%	19.7%	25.2%	23.0%	18.6%	10.4%
Corporate and Other	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
TOTAL CHEMOURS	24.8%	27.1%	23.0%	25.0%	24.1%	22.7%	19.8%	15.2%	18.1%	19.2%	13.5%	9.9%

* Note: Individual quarters may not sum to the last twelve months (LTM) or full year amounts due to rounding.

SEGMENT NET ASSETS
(Dollars in millions)

	Full Year 2017	Full Year 2016
Fluoroproducts	$ 1,842	$ 1,400
Chemical Solutions (1)	460	292
Titanium Technologies	1,785	1,513
Corporate and Other	(3,222)	(3,101)
TOTAL CHEMOURS	$ 865	$ 104

(1) As of December 31, 2016, Chemical Solutions' net assets were reduced by approximately $415 in connection with the sales of our Clean & Disinfect and Sulfur businesses during 2016. For further details, refer to Note 7 of the Consolidated Financial Statements included in our Annual Report on Form 10-K as of and for the year ended December 31, 2017.

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

(Dollars in millions, except per share amounts)

RECONCILIATION OF NET INCOME (LOSS) ATTRIBUTABLE TO CHEMOURS TO ADJUSTED NET INCOME AND ADJUSTED EBITDA

	LTM* 1Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Net income (loss) attributable to Chemours	**$ 893**	$ 297	**$ 746**	$ 228	$ 207	$ 161	$ 150	**$ 7**	$ (230)	$ 204	$ (18)	$ 51
Non-operating pension and other post-retirement employee benefit income	**(34)**	(7)	**(34)**	(10)	(7)	(10)	(8)	**(20)**	(1)	(5)	(7)	(7)
Exchange losses (gains)	**2**	-	**(3)**	-	4	(2)	(5)	**57**	20	17	14	6
Restructuring, asset-related, and other charges, net	**55**	10	**57**	26	8	11	12	**51**	11	14	9	17
Asset-related charges (1)	**3**	-	**3**	-	1	2	-	**124**	14	46	63	-
(Gain) loss on sale of assets or businesses (2)	**(48)**	(42)	**(22)**	(8)	-	2	(16)	**(254)**	3	(169)	1	(89)
Transaction costs (3)	**3**	-	**3**	-	1	2	-	**19**	1	2	12	3
Legal and other charges (4)	**16**	4	**18**	-	7	5	7	**359**	336	5	13	5
Adjustments made to income taxes (5,7)	**(21)**	(5)	**(25)**	(3)	(11)	(2)	(10)	**18**	18	-	-	-
(Benefit from) provision for income taxes relating to reconciling items (6,7)	**(5)**	9	**(14)**	(4)	(5)	(5)	1	**(148)**	(139)	(5)	(5)	1
Adjusted Net Income	**864**	266	**729**	229	205	164	131	**213**	33	109	82	(13)
Net income attributable to non-controlling interests	**-**	-	**1**	-	-	-	1	**-**	-	-	-	-
Interest expense, net	**216**	52	**215**	54	55	55	51	**213**	56	51	50	57
Depreciation and amortization	**272**	70	**273**	69	62	71	71	**284**	72	73	73	66
All remaining provision for (benefit from) income taxes (7)	**252**	80	**204**	42	59	71	31	**112**	78	35	(18)	18
Adjusted EBITDA	**$ 1,604**	$ 468	**$ 1,422**	$ 394	$ 381	$ 361	$ 285	**$ 822**	$ 239	$ 268	$ 187	$ 128
Adjusted basic earnings per share	**$ 4.69**	$ 1.46	**$ 3.95**	$ 1.23	$ 1.11	$ 0.89	$ 0.72	**$ 1.17**	$ 0.18	$ 0.60	$ 0.45	$ (0.07)
Adjusted diluted earnings per share	**4.53**	1.41	**3.82**	1.19	1.07	0.86	0.70	**1.16**	0.18	0.59	0.45	(0.07)

(1) The year ended December 31, 2016 includes pre-tax impairment charges of $13 and $58 associated with the sales of our corporate headquarters building located in Wilmington, Delaware and Sulfur business, respectively, and $48 in pre-tax impairment charges associated with our aniline facility in Pascagoula, Mississippi, as well as certain other asset write-offs.

(2) For the three months ended March 31, 2018, gain on sale includes a $42 gain associated with the sale of our Linden, New Jersey site. The year ended December 31, 2017 includes gains of $13 and $12 associated with meeting certain milestones in connection with our sale of land in Repauno, New Jersey, and for the sale of our Edge Moor, Delaware plant site, respectively, net of certain losses on other disposals. The year ended December 31, 2016 includes gains of $169 and $89 associated with the sales of our C&D business and aniline facility in Beaumont, Texas, respectively.

(3) Includes accounting, legal, and bankers' transaction fees incurred related to our strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of the C&D and Sulfur businesses during 2016.

(4) Includes litigation settlements, water treatment accruals, and other charges. The year ended December 31, 2016 includes $335 in litigation accruals associated with the PFOA MDL Settlement.

(5) Includes the removal of certain discrete income tax impacts within our provision for (benefit from) income taxes. For 2018, the adjustment of $5 related entirely to windfall benefits on our share-based payments. For 2017, the adjustment is primarily attributable to a benefit of $20 related to windfall benefits on our share-based payments, the reversal of a reserve for uncertain tax positions of $6, and a benefit for the net impact of U.S. tax reform of $3, which are partially offset by foreign exchange gains and losses of $5. For 2016, the adjustment of $18 related entirely to tax implications of foreign exchange gains and losses.

(6) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

(7) The total provision for (benefit from) income taxes reconciles to the amount reported in the consolidated statements of operations for each of the respective periods.

* Note: Individual quarters may not sum to the last twelve months (LTM) or full year amounts due to rounding.

RECONCILIATION OF FREE CASH FLOWS

	LTM* 1Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Cash flows provided by operating activities (1)	$ 794	$ 196	**$ 639**	$ 303	$ 112	$ 183	$ 41	**$ 594**	$ 269	$ 199	$ 90	$ 36
Less: Purchases of property, plant, and equipment	(444)	(102)	**(411)**	(165)	(108)	(69)	(69)	**(338)**	(103)	(67)	(79)	(89)
Free Cash Flows (1)	$ 350	$ 94	**$ 228**	$ 138	$ 4	$ 114	$ (28)	**$ 256**	$ 166	$ 132	$ 11	$ (53)

(1) Cash flows provided by operating activities for the year ended December 31, 2017 include $335 in payments related to the PFOA MDL Settlement. Cash flows provided by operating activities for the year ended December 31, 2016 include $190 in prepayments from DuPont, of which $58 was outstanding at December 31, 2016. The DuPont prepayment was fully utilized during the year ended December 31, 2017.

* Note: Individual quarters may not sum to the last twelve months (LTM) or full year amounts due to rounding.

Chemours™

ADJUSTED NET INCOME AND ADJUSTED EBITDA RECONCILING ITEMS BY FINANCIAL STATEMENT LINE ITEM (UNAUDITED)

(Dollars in millions)

		1Q18				1Q17			
Reconciling Items	Statements of Operations Categories (1)	Total	COGS	SG&A	Other	Total	COGS	SG&A	Other
Non-operating pension and other post-retirement employee benefit income	Other income, net	**$ (7)**	$ -	$ -	$ (7)	**$ (8)**	$ -	$ -	$ (8)
Exchange gains	Other income, net	**-**	-	-	-	**(5)**	-	-	(5)
Restructuring, asset-related, and other charges, net	Restructuring	**10**	-	-	10	**12**	-	-	12
Gain on sale of assets or businesses	Other income, net	**(42)**	-	-	(42)	**(16)**	-	-	(16)
Legal and other charges	SG&A	**4**	-	4	-	**7**	-	7	-
Adjustments made to income taxes	Provision for income taxes	**(5)**	-	-	(5)	**(10)**	-	-	(10)
Provision for income taxes relating to reconciling items	Provision for income taxes	**9**	-	-	9	**1**	-	-	1
Total Adjusted Net Income reconciling items		**(31)**	**-**	**4**	**(35)**	**(19)**	**-**	**7**	**(26)**
Net income attributable to non-controlling interests	NCI	**-**	-	-	-	**1**	-	-	1
Interest expense, net	Interest expense, net	**52**	-	-	52	**51**	-	-	51
Depreciation and amortization	COGS / SG&A	**70**	63	7	-	**71**	63	8	-
All remaining provision for income taxes	Provision for income taxes	**80**	-	-	80	**31**	-	-	31
Total Adjusted EBITDA reconciling items		**$ 171**	**$ 63**	**$ 11**	**$ 97**	**$ 135**	**$ 63**	**$ 15**	**$ 57**

(1) Abbreviated Statements of Operations Categories represent the following financial statement line items in the statements of operations:

- COGS - Cost of goods sold
- SG&A - Selling, general, and administrative expense
- Restructuring - Restructuring, asset-related, and other charges, net
- NCI - Net income attributable to non-controlling interests

Chemours™

RETURN ON INVESTED CAPITAL RECONCILIATION (UNAUDITED)
(Dollars in millions)

	Three Months Ended March 31,		Year Ended December 31,	
	2018	2017	2017	2016
Adjusted EBITDA (1)	$ 1,605	$ 979	$ 1,422	$ 822
Less: Depreciation and amortization (1)	(272)	(289)	(273)	(284)
Adjusted EBIT	1,333	690	1,149	538
Total debt	4,155	3,552	4,112	3,544
Total equity	1,002	358	865	104
Less: Cash and cash equivalents	(1,434)	(898)	(1,556)	(902)
Invested capital, net	$ 3,723	$ 3,012	$ 3,421	$ 2,746
Average invested capital (2)	$ 3,327	$ 3,257	$ 3,157	$ 3,419
Return on Invested Capital	40.1%	21.2%	36.4%	15.7%

(1) Based on amounts for the trailing twelve months ended March 31, 2018 and 2017 and December 31, 2017 and 2016. Reconciliations of Adjusted EBITDA to net income (loss) attributable to Chemours are provided on quarterly and full year bases. See the preceding table for the reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three months ended March 31, 2018 and 2017 and for the years ended December 31, 2017 and 2016.

(2) Average invested capital is based on a five-quarter trailing average of invested capital, net.